File: '\\swfile\EmailIn\20240418 201426 Attachment 2024_04_18 Early warning news - Entheon Biomedical Corp. - Blair Naughty.docx'

NEWS RELEASE

CANAL FRONT INVESTMENTS INC. ACQUIRES SECURITIES OF

ENTHEON BIOMEDICAL CORP.

Vancouver, British Columbia, April 18, 2024 - Canal Front Investments Inc. (the "Acquiror") announces the acquisition of ownership and control of 900,000 common shares (the "Subject Shares") and 900,000 common share purchase warrants (the "Subject Warrants" and together with the Subject Shares, the "Subject Units") of Entheon Biomedical Corp. (the "Company"). The Subject Shares represented approximately 10.16% of all issued and outstanding common shares of the Company as of April 18, 2024, immediately following the transaction described above (or approximately 20.32% on a partially diluted basis, assuming exercise of the Subject Warrants only), resulting in a corresponding increase in the percentage of shares held by the Acquiror as a result of the transaction.

Immediately before the transaction described above, the Acquiror held 10,000 common shares of the Company (the "Pre-Shares").

Immediately following the transaction described above, the Acquiror held an aggregate of 910,000 common shares (the "Post-Shares") and convertible securities entitling the Acquiror to acquire an additional 900,000 common shares of the Company (the "Post-Convertible Securities"), representing approximately 10.27% of the issued and outstanding common shares of the Company (or approximately 20.43% assuming exercise of such Post-Convertible Securities only).

The aggregate consideration payable for the Subject Units was $45,000, or $0.05 per Subject Unit. The Subject Units were acquired in a non-brokered private placement financing transaction which does not contain any provisions regarding the transfer, guarantee or voting of such securities.

The holdings of securities of the Company by the Acquiror are managed for investment purposes. The Acquiror may from time to time acquire additional securities of the Company, dispose of some or all of the existing or additional securities they hold or will hold, or may continue to hold their current positions.

Additional Information

A copy of the applicable securities report filed in connection with the matters set forth above may be obtained on SEDAR+ under the profile of Entheon Biomedical Corp.